Pfizer has launched Zavicefta (ceftazidime-avibactam) for adults hospitalised with serious infections caused by aerobic Gram-negative bacteria. Zavicefta combines the beta-lactam antibiotic ceftazidime with the beta-lactamase inhibitor, avibactam.

Pfizer says that ceftazidime-avibactam is effective against some “resistant aerobic Gram-negative pathogens of greatest global concern”, such as carbapenem-resistant Enterobacteriaceae and multi-drug resistant Pseudomonas aeruginosa.